Drugs for bad bugs: Confronting the challenges of antibacterial discovery

Nature Reviews Drug Discovery

Volumn 6, Issue 1, 2007, Pages 29-40

  Payne, David J ^a   Gwynn, Michael N ^a   Holmes, David J ^a   Pompliano, David L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE; METHANOL DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUMATRIPTAN SUCCINATE; TETRACYCLINE DERIVATIVE; TRYPTOLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENOME; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG DESIGN; GENOMICS; HUMANS;

EID: 33845903833     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2201     Document Type: Review

References (34)

1. House of Lords Select Committee on Science and Technology Seventh Report. Resistance to Antibiotics and Other Antimicrobial Agents [online], (Stationary Office, London, UK, 1998).
2. Shlaes, D. M. et al. Antibiotic discovery: State of the state. ASM News 70, 275-281 (2004).
3. Talbot, G. H. et al. Bad bugs need drugs: An update on the development pipeline from the antibacterial availability task force of the IDSA. Clin. Infect. Dis. 42, 657-668 (2006).
4. Wenzel, R. P. The antibiotic pipeline - challenges, costs, and values. N. Engl. J. Med. 351, 523-526 (2004).
5. Infectious Disease Society of America. Bad Bugs, No Drugs [online], (2004).
6. Tickell, S. The Antibiotic Innovation Study: Expert Voices on a Critical Need [online], (2005).
7. Nathan, C. Antibiotics at the cross roads. Nature 431, 899-902 (2004).
8. Kaplan, W. & Laing, R. Priority Medicines for Europe and the World [online], (World Health Organization, Geneva, 2004).
9. Brown, J. R. & Warren, P. V. Antibiotic discovery: Is it in the genes? Drug Discov. Today 3, 564-566 (1998).
10. Chan, P. F., Macarron, R., Payne, D. J., Zalacain, M. & Holmes, D. J. Novel antibacterials: A genomics approach to drug discovery. Curr. Drug Targets - Infect. Dis. 2, 109-119 (2002).
11. Chan, P. F. et al. Characterization of a noval fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode of action studies in Streptococcus pneumoniae. J. Bacteriol. 185, 2051-2058 (2003).
12. Zhang, L. et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 255, 297-305 (2000).
13. Yin, D. et al. Identification of Antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics 5, 101-113 (2004).
14. Zalacain, M. et al. A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol. Biotechnol. 6, 109-126 (2003).
15. Jarvest, R. L., et al. Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against Grampositive pathogens. J. Med. Chem. 45, 1959-1962 (2002).
16. Payne, D. J. et al. Discovery of a novel and potent class of FabI directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124 (2002).
17. Fan, F. et al. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3343-3347 (2002).
18. Aubert, K. & Zalacain, M. 3 Peptide deformylase inhibitors. Prog. Med. Chem. 44, 109-143 (2006).
19. Gentry, D. R. et al. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob. Agents Chemother. 47, 1784-1789 (2003).
20. Du, W. et al. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. J. Bacteriol. 182, 4146-4152 (2000).
21. Heath, R. J. & Rock, C. O. A triclosan-resistant bacterial enzyme. Nature 406, 145 (2000).
22. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Rosenberg, M. Genomic approaches to antibacterial discovery. Methods Mol. Biol. 266, 231-259 (2004).
23. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
24. Heerding, D. A. et al. New benzylidenethiazolidinedoines as antibacterial agents. Bioorg. Med. Chem. Lett. 13, 3771-3773 (2003).
25. Chan, P. F. et al. Finding the gems using genomic discovery: antibacterial drug discovery strategies - the successes and the challenges. Drug Discov. Today: Ther. Strategies 1, 519-527 (2004)
26. Pace, N. R., A molecular view of microbial diversity and the biosphere. Science 276, 734 (1997).
27. Wong, K. K. et al. Engineering a cell-free murein biosynthetic pathway: combinatorial enzymology in drug discovery. J. Am. Chem. Soc. 120, 13527-13528 (1998).
28. DeVito, J. A. et al. An array of target-specific screening strains for antibacterials discovery. Nature Biotechnol. 20, 478-483 (2002).
29. Wong, K. K. & Pompliano, D. L. in Resolving the Antibiotic Paradox: Progress in Understanding Drug Resistance and Development of New Antibiotics (eds Rosen, B. P. & Mobashery, S.) (Plenum, New York, 1999)
30. Feher, M. & Schmidt, J. M. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218-227 (2003).
31. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computional approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
32. Walsh, C. T. Combinatorial biosynthesis of antibiotics: Challenges and opportunities. Chembiochem 3, 125-134 (2002)
33. Throup, J. P. et al. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol. Microbiol. 35, 566-576 (2000).
34. Ji Y. et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293, 2266-2269 (2001)